Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX
· Real-Time Price · USD
2.00
0.05 (2.56%)
At close: Jun 06, 2025, 3:52 PM
2.05
2.50%
After-hours: Jun 06, 2025, 04:17 PM EDT
Company Description
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases.
It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.
The company was founded by Gregory L.
Verdine, Rosana Kapeller, Huw M.
Nash, Joseph A.
Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Rein Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 29, 2017 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. James Brian Windsor Ph.D. |
Contact Details
Address: 12407 N. Mopac Expy. Austin, United States | |
| Website | http://www.reintx.com |
Stock Details
| Ticker Symbol | RNTX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001420565 |
| CUSIP Number | 00887A204 |
| ISIN Number | US00887A2042 |
| Employer ID | 13-4196017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James Brian Windsor Ph.D. | Chief Executive Officer, President & Director |
| Dr. Cory M. Hogaboam Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2025 | S-3 | Filing |
| May 14, 2025 | SCHEDULE 13G | Filing |
| May 12, 2025 | ARS | Filing |
| May 12, 2025 | DEFA14A | Filing |
| May 12, 2025 | DEF 14A | Filing |
| Apr 30, 2025 | 10-K/A | [Amend] Annual Report |
| Apr 22, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 07, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | NT 10-K | Filing |